What is the Optimal Design-Build-Test Cycle for Clinically Relevant Synthetic CAR T Cell Therapies?
Cell Syst
.
2020 Sep 23;11(3):212-214.
doi: 10.1016/j.cels.2020.08.017.
Authors
Yvonne Y Chen
,
Wendell Lim
,
Megan Levings
,
Bruce Blazar
,
Giedre Krenciute
,
Wilson Wong
,
Manfred Lehner
PMID:
32970992
PMCID:
PMC7861890
DOI:
10.1016/j.cels.2020.08.017
No abstract available
MeSH terms
Humans
Immunotherapy / methods*
Receptors, Antigen, T-Cell / metabolism*
Substances
Receptors, Antigen, T-Cell
Grants and funding
P50 CA211015/CA/NCI NIH HHS/United States